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naire” (PBQ), both containing identical items with different wording. Data were
obtained from two studies, one being a cross-sectional study on n2,009 patients,
the other a prospective observational therapeutic study on n93 patients. Treat-
ment goals and benefits were used to calculate the overall preference-based Patient
Benefit Index (PBI). RESULTS: In both studies, the PNQ showed a variety of high
therapeutic needs from the perspective of the psoriasis patients. The PBQ ques-
tionnaire revealed that under routine treatment only a part of the patient-defined
goal were achieved. The resulting PBI depended on the treatment applied. Higher
values were observed in systemic treatments, in particular in biologics. The PBI was
feasible with a rate of missing values 1.5% in PNQ and 2.0% in PBQ. The sub-
scales of the PBI were internally consistent (Cronbach’s alpha 0.68 – 0.87). The PBI
showed satisfying convergent validity with respect to correlation with changes in
QoL (delta DLQI) and PASI. Moreover, correlation with separate single items on
treatment benefit (anchoring variables) was markedly high (r0.75, r0.65,
p0.001). CONCLUSIONS: The Patient Benefit Index (PBI) is a valid, reliable and
suitable instrument for the assessment of patient-reported benefit in the treat-
ment of psoriasis.
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OBJECTIVES: Although there are a range of established outcomes measures for
psoriasis in general, there has been a lack of valid instruments for nail psoriasis
(NPso). Therefore, we developed and validated the three-component tool “Nail
Assessment in Psoriasis and Psoriatic Arthritis” (NAPPA) including health-related
quality of life (NAPPA-QoL), patient-relevant treatment benefit (NAPPA-PBI) and
clinical severity (NAPPA-CLIN). METHODS: The NAPPA tool was developed by a
multinational expert group involving dermatologists, psychologists, statisticians,
and patients. Development included the following steps: 1) Open item collection on
patient-relevant impairments and needs in n120 patients in 2 countries (D, USA);
2) item development by an expert panel including patients; 3) double forward and
backward translations with subsequent translators’ and developers’ conferences;
4) feasibility testing of the pilot questionnaire in n55 patients in 4 countries (D,
USA, Canada, UK) with subsequent questionnaire refinement; 5) longitudinal fea-
sibility and validation study in n203 patients from 6 countries (Germany, USA,
Denmark, Japan, Italy, Spain). RESULTS: Open item collection generated 692 single
items with redundant content which could be condensed to 20 items for the
NAPPA-QoL and 24 items for the NAPPA-PBI. Most patients rated the final question-
naires as feasible, i.e. the purpose was clear to them (95.0%), instructions and
questions were comprehensible (83.6% / 89.1%), and all relevant areas were covered
(87.1%). NAPPA-QoL and -PBI correlated moderately with clinical outcomes (PASI,
NAPSI) but markedly with other QoL questionnaires (EQ-5D, DLQI). Sensitivity to
change and internal consistency were good. Clinical severity (NAPPA-CLIN) was
measured with a two-digit solution which correlated highly (r0.9) with NAPSI but
which can be assessed much more time-efficiently. CONCLUSIONS:With the mod-
ular NAPPA outcomes tool, clinical and patient-reported outcomes in nail psoriasis
can be measured validly and reliably. Thus, it can be recommended for usage in
international clinical studies and daily practice.
PSS27
DO SCARS IMPACT BEYOND JUST APPEARANCE? A REPORT OF THE CONTENT
ELICITATION (CE) PHASE IN THE DEVELOPMENT OF THE PATIENT REPORTED
SCAR EVALUATION QUESIONNAIRE (PR-SEQ)
Pleil A1, Jensen J1, Galipeau N2, Olude O2, Klemm M2, Shields A2
1Pfizer, Inc., San Diego, CA, USA, 2Adelphi Values, Boston, MA, USA
OBJECTIVES: Currently available scar assessment tools focus on the appearance
and symptoms of scars but avoid the complete scar experience. Additionally, ex-
isting instruments lack evidence or documentation (or both) of their development
(e.g., content validity) and performance (e.g., reliability, construct-related validity,
and responsiveness), and it is unlikely they would meet current regulatory require-
ments for labeling. The objective of the present work was to conduct qualitative
research with patients to better understand scar appearance, symptoms, and im-
pacts, and to use those results to inform the development of a content-valid PRO
instrument for use in clinical trials. METHODS: Eight physicians (3 dermatologists
and 5 plastic surgeons) recruited subjects to participate in the CE research activi-
ties. Each subject (aged 18 to 65) was required to have a linear surgical (cosmetic or
non-cosmetic) scar below the neck. Subjects with burn scars were excluded as were
subjects with significant medical comorbidities. The interviews were conducted in
multiple cities in the United States, transcribed, and used to derive the scar ques-
tionnaire items. RESULTS: A total of 43 interviews across five surgery types were
conducted to elicit information regarding their experiences with their disfiguring
scar. During the CE interviews, the most important and relevant concepts patients
used to describe scar appearance were color, size (height, width, thickness), and
texture. The most important and relevant scar symptom concepts reported were
itchiness and pain. The most important, relevant, and bothersome scar impact
concepts were limitations of wearing certain clothing and feeling self-conscious,
sad, and less attractive because of the scar. CONCLUSIONS: The CE interviews
provided rich information about how patients perceive and experience their scars
which extends beyond the typical appearance dimensions. This work is fundamen-
tal in providing the basis for the conceptual framework of the scar experience and
the first steps in the development of the PR-SEQ.
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OBJECTIVES:We describe Week 52 quality of life outcomes following immediate or
gradual transition to ustekinumab in psoriasis patients with inadequate response
to methotrexate in the Phase IV TRANSIT study (NCT01059773). METHODS: In this
52-week, open-label trial, 490 patients with moderate-to-severe plaque psoriasis
despite treatment with methotrexate (10–25mg/week for 8 weeks) were ran-
domised 1:1 to ustekinumab with immediate cessation of methotrexate (Arm1), or
4 weeks’ overlap with decreasing methotrexate dose (Arm2). Ustekinumab was
administered according to label: 45mg in patients 100kg or 90mg if 100kg. Pa-
tients 100kg not achieving adequate response (Psoriasis Area Severity Index de-
crease from baseline 75% [PASI 75]) at Weeks 28 or 40 were dose escalated to
90mg. RESULTS: A total of 244 patients were treated in Arm1 and 245 in Arm2; 92%
and 90%, respectively, completed 52 weeks’ therapy. Median baseline Dermatology
Life Quality Index (DLQI) was 8 and 9 in Arms1 and 2, respectively, decreasing to 1
(both arms) at Weeks 16 and 52. At Week 52 in Arms1 and 2, respectively, 61% and
62% of patients had a DLQI reduction 5 points; 62% and 67% had DLQI 0 or 1.
Median DLQI scores were low at Week 28 among patients who dose escalated;
further improvements were seen by Week 52. Median EuroQOL-5D Visual Analogue
Scale improved from baseline to Week 52, respectively: 70.0 (IQR 50.0–80.0) to 85.0
(IQR 70.0–95.0) in Arm1, and 70.0 (IQR 50.0–85.0) to 85.0 (IQR 79.5–95.0) in Arm2.
Median Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression
scores also improved from baseline to Week 52. CONCLUSIONS: In patients with
moderate-to-severe psoriasis, ustekinumab use was associated with clinically rel-
evant improvements in patient-reported outcomes, irrespective of whether pa-
tients were transitioned with immediate or gradual cessation of methotrexate.
Improvements at Week 16 were sustained to 52 weeks of ustekinumab therapy.
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OBJECTIVES: To investigate whether a 1-line (5 letters) average change in best
corrected visual acuity (BCVA) is associated with changes in health-related quality
of life (HRQoL) in patients with diabetic macular edema (DME). METHODS: Data
from a 12-month randomized trial of dexamethasone intravitreal implant plus
laser or laser alone for DME were analyzed. HRQoL was assessed by the National
Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). Patients were cate-
gorized into groups based on time-weighted average BCVA change from baseline:
worsened (	BCVA -5), no change (-5 	BCVA5) and improved (	BCVA5). Av-
erage change in VFQ-25 composite score and 11 subscales were compared using
ANCOVA analysis controlling for baseline BCVA and VFQ-25 scores. Proportions of
patients achieving 5-point improvement in VFQ-25 composite score and 4 sub-
scales closely associated with central vision (general vision, near activities, distant
activities, and mental health) were also compared. Similar analyses were con-
ducted for subgroups of better-seeing eye (BSE) and worse-seeing eye (WSE) pa-
tients, respectively. RESULTS: A total of 252 (18.3% BSE and 81.7% WSE) patients
had a mean VFQ-25 composite score of 69.1 at baseline. Compared to the no change
BCVA group, the improved group had 3.2-6.7 points (p0.048) greater average
changes in VFQ-25 composite score and 4 subscales (general vision, near activities,
dependency, and driving ); the corresponding differences were greater (10.2-18.3
points, p0.019) among BSE patients except in general vision. The worsened, no
change, and improved BCVA groups showed a statistically different (p0.038) and
increasing trend in achieving 5-point improvement in the 4 VFQ-25 subscales
examined except in distant activities. CONCLUSIONS: Previous literature based on
BSE visual acuity has defined minimally important differences in VFQ-25 score
ranging from 3 to 5 points. The current study suggests a 1-line average improve-
ment in BCVA was associated with clinically meaningful changes in HRQoL among
DME patients.
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